Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin extended release - Assertio Therapeutics

Drug Profile

Ciprofloxacin extended release - Assertio Therapeutics

Alternative Names: Ciprofloxacin controlled release - Assertio Therapeutics; Ciprofloxacin gastric retention; Ciprofloxacin GR; Ciprofloxacin hydrochloride extended release - Assertio Therapeutics; Ciprofloxacin hydrochloride prolonged-release tablets - Assertio Therapeutics; Proquin XR; URITENT; UTIMINX

Latest Information Update: 04 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Depomed
  • Developer Assertio Therapeutics
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Urinary tract infections

Highest Development Phases

  • Market Withdrawal Urinary tract infections

Most Recent Events

  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 31 Oct 2010 Withdrawn for Urinary tract infections in USA (PO)
  • 24 Jul 2008 Registered for Urinary tract infections in Sweden (PO, Controlled release, 500mg, Once daily)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top